Trial Profile
Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacodynamics; Pharmacogenomic
- 25 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2011 Results presented at the Digestive Disease Week 2011.